je.st
news
OncoGenex Is A Buy As Thesis Remains Intact
2015-05-26 15:22:15| Logistics - Topix.net
In addition to the potential for news at ASCO and the company call discussing the data after the event, the second futility analysis for ENSPIRIT provides near-term upside potential. With over $40 million in cash at Q1 end and greater than $23 million recently received from Teva, OncoGenex is grossly undervalued at its current sub-$45 million market cap.
Tags: buy
remains
thesis
intact
Category:Transportation and Logistics